Predictmedix Successfully Closes First Tranche of Private Placement, Raising $320,000
Toronto, Ontario – Predictmedix AI Inc. (CSE: PMED, OTC: PMEDF, FRA: 3QP) (“Predictmedix” or the “Company”), a pioneering health tech company specializing in AI-driven health screening solutions, announced the successful completion of the first tranche of its non-brokered private placement. The offering included the issuance of 16,000,000 Units at a price of $0.02 per Unit.
Details of the Private Placement
Each Unit comprises one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). The Warrants are exercisable at a price of $0.05 per Common Share for a term of five years from the date of issuance. The net proceeds from the offering will be utilized for working capital and general corporate purposes.
Impact on Predictmedix
This private placement will significantly bolster Predictmedix’s financial position, enabling the company to further advance its AI-powered health screening solutions and expand its reach in the market. The funds will be used to strengthen the team, develop new products, and initiate marketing campaigns to increase brand awareness.
Global Implications
The successful closing of this private placement is a testament to the growing interest in AI-driven health solutions. Predictmedix’s innovative approach to health screening, using artificial intelligence to identify early signs of various health conditions, has the potential to revolutionize the way healthcare is delivered. This development, in turn, could lead to improved health outcomes, increased efficiency in healthcare systems, and reduced healthcare costs.
Conclusion
Predictmedix’s successful first tranche of its non-brokered private placement marks an exciting milestone for the company as it continues to push the boundaries of AI-driven health screening solutions. This investment not only strengthens Predictmedix’s financial position but also underlines the growing demand for advanced, efficient, and cost-effective healthcare solutions. As the world grapples with the challenges of aging populations and rising healthcare costs, Predictmedix’s technology could play a pivotal role in transforming the healthcare landscape. Stay tuned for further updates as the company continues to make strides in the field of AI health screening.
- Predictmedix successfully closes first tranche of non-brokered private placement
- Raised $320,000 through issuance of 16,000,000 Units
- Each Unit consists of one Common Share and one Common Share purchase warrant
- Net proceeds to be used for working capital and general corporate purposes
- Funds will enable advancements in AI-powered health screening solutions
- Potential to revolutionize healthcare delivery, improve health outcomes, and reduce costs
